Short answer
MAXCYTE, INC. (MXCT) filed an 8-K current report with the SEC on November 10, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition), Item 3.02 (Unregistered Sales of Equity Securities), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item EX-99.3 (Exhibit EX-99.3), Item EX-99.4 (Exhibit EX-99.4). MaxCyte acquiring Akron BioProducts for $105.0M cash, 20,639,733 shares, and $20.0M deferred cash.
MAXCYTE, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- MaxCyte acquiring Akron BioProducts for $105.0M cash, 20,639,733 shares, and $20.0M deferred cash
- Deferred payments split into $10.0M due in 2028 and $10.0M due in 2029, adding future cash obligations
- Closing expected before year-end 2026, pending antitrust clearance and Nasdaq approval for issued shares
- No financing or stockholder approval condition, reducing execution dependencies
- Stock consideration locked up six months, with seller resale registration rights creating potential dilution overhang
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 results for quarter ended September 30, 2026 announced November 10, 2026
- Press release contains the financial results and accompanying investor-relevant disclosures
- Exhibit 99.1 provides the detailed quarterly performance information
Item 3.02 · Unregistered Sales of Equity Securities
- 20,639,733 MXCT shares to be issued to sellers as stock consideration at transaction closing
- Private placement under Securities Act Section 4(a)(2), avoiding public registration
- Significant potential dilution for existing shareholders, with shares issued to accredited-investor sellers
Item 7.01 · Regulation FD Disclosure
- Acquisition announcement, investor presentation, and corporate presentation released November 10, 2026
- Closing depends on Hart-Scott-Rodino waiting-period expiration or termination
- Akron integration and expected benefits remain execution risks
- Stock consideration could dilute existing holders and pressure shares after lock-up expiration
- Anticipated senior secured debt and deferred cash payments add leverage and liquidity risk
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $10.2M, up 49%, with core revenue $8.2M up 27% and SPL revenue $2.0M
- Gross margin improved to 83% from 77%, while operating expenses fell to $14.5M from $19.4M
- Net loss narrowed to $4.8M from $12.4M, but EBITDA remained negative at $5.1M
- 2026 revenue guidance raised to at least $34.5M, including approximately $28M core revenue and at least $6.5M SPL revenue
- Proposed Akron Bio acquisition requires $105.0M cash and deal expenses plus $22.0M credit-facility borrowing, reducing expected year-end liquidity to $40.0M-$45.0M
Item EX-99.2 · Exhibit EX-99.2
- Acquisition of Akron Bio for $151.8M, expected to close before year-end 2026
- Akron projected 2026 revenue $28M and EBITDA $7M-$8M, adding recurring consumables revenue
- Consideration includes $105M cash, 20,639,733 shares worth $26.8M, and $20M deferred payments
- New MidCap facility up to $75M, with $22M expected initial draw, increasing leverage and debt obligations
- Combined company expects annual cash burn below $10M in 2027 and profitability without fully using facility
Item EX-99.3 · Exhibit EX-99.3
- Acquisition consideration ~$151.8M: $105.0M cash, 20.6M shares, and $20.0M deferred payments in 2028–2029
- Akron adds $28M expected 2026 revenue, $7M–$8M EBITDA, and positive cash flow to roughly double MaxCyte’s revenue base
- Financing includes $55.0M term loan and $20.0M revolver, with expected initial draws of $20.0M and $2.0M
- Combined recurring revenue mix rises from 57% to 74%, while largest-customer concentration falls from 27% to 14%
- Commercial and registrational programs expand from 4 to 12, including 5 approved therapies; closing expected before year-end 2026
Item EX-99.4 · Exhibit EX-99.4
- Corporate presentation highlights 3Q26 core revenue $8.157M, up 27% year over year
- YTD 2026 total revenue $27.074M, up 5%, while core revenue declined 9% to $20.877M
- SPL-related revenue $6.197M YTD, up 115%, increasing reliance on milestone-driven partner economics
- Cash, equivalents and investments $133M as of September 30, 2026, supporting continued investment and cash-burn reduction
- Installed instrument base reached 936, expanding future recurring disposable and license revenue potential
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other MAXCYTE, INC. 8-K filings
Get the next MXCT 8-K as it lands
Follow MXCT for push alerts, or ask the research agent what this filing means.